Quibim has secured $50 million in Series A financing, led by Asabys and Buenavista, to enhance its AI-driven imaging solutions and expand its presence in the U.S. healthcare market.

Target Information

Quibim is a groundbreaking healthtech company that specializes in utilizing imaging biomarkers for precision medicine. The company has developed advanced artificial intelligence (AI) models that analyze imaging data from MRI, CT, and PET scans, extracting insightful information to facilitate precise patient diagnoses and treatment recommendations. Quibim's ambitious goal is to achieve a comprehensive, non-invasive understanding of human tissues at any moment, a vision that could revolutionize health monitoring and improve patient stratification.

The company's flagship products include QP-Prostate, QP-Brain, and QP-Liver, which all cater to distinct clinical challenges in oncology, neurology, and liver diseases. Quibim’s innovative approach has enabled it to establish over 170 installations in renowned global institutions, effectively bridging the gap between research and practical clinical applications.

Industry Overview

The healthtech industry in Spain is rapidly evolving, characterized by a surge in innovation aimed at integrating advanced technologies into health services. The Spanish healthcare system heavily emphasizes patient-centric care, pu